Table 2 Characteristics of patients with CC398 PJI
From: Epidemiology and risk factors of Staphylococcus aureus CC398 bone and joint infections
CC 398 PJI (n = 23) | Non CC 398 PJI (n = 121) | Univariate | Multivariate | ||
|---|---|---|---|---|---|
P value | P value | OR (IC 95%) | |||
Age (years), mean ± SD | 67.7 (±12.3) | 73.6 (±12.3) | 0.041 | 0.034 | 0.9 (0.9–0.99) |
Male sex, n (%) | 11 (48) | 65 (54) | 0.77 | ||
Mc Cabe Score | |||||
Non fatal, n (%) | 18 (78) | 114 (94.2) | 0.016 | 0.005 | 5.1 (1.6–15.3) |
Ultimately fatal, n (%) | 5 (22) | 6 (5) | |||
Rapidly fatal, n (%) | 0 (0) | 1 (0.8) | |||
MSSA, n (%) | 23 (100) | 108 (89) | 0.13 | ||
Charlson’s comorbidity score, mean ± SD | 2.04 (±1.89) | 1.56 (±1.61) | 0.27 | ||
Year of infection | |||||
2010 | 2 (8.7) | 14 (11) | 0.1 | NT | |
2011 | 2 (8.7) | 9 (7.3) | |||
2012 | 2 (8.7) | 18 (15) | |||
2013 | 4 (17) | 13 (11) | |||
2014 | 1 (4.3) | 17 (14) | |||
2015 | 2 (8.7) | 16 (13) | |||
2016 | 2 (8.7) | 24 (20) | |||
2017 | 8 (35) | 12 (9.8) | |||
Recent hospitalisation (< 1 yr), n (%) | 13 (57) | 74 (60) | 0.92 | ||
BJI Type | |||||
Shoulder, n (%) | 1 (4.3) | 5 (4.1) | 1 | ||
Hip, n (%) | 16 (70) | 75 (62) | 0.65 | ||
Knee, n (%) | 6 (26) | 40 (33) | 0.68 | ||
Ankle, n (%) | 0 | 1 (0.8) | 1 | ||
Chronic BJI (i.e. evolution delay > 4 weeks) | 5 (28) | 51 (42) | 0.37 | ||
Occurrence of infection after primary arthroplasty | |||||
Delay (months) | 23 (±49.3) | 44.4 (±59.2) | 0.023 | NT | |
< 3 months, n (%) | 14 (61) | 44 (36) | 0.049 | NT | |
3–12 months, n (%) | 3 (13) | 17 (14) | 1 | ||
12 months, n (%) | 7 (30) | 60 (50) | 0.14 | ||
Bacteremia, n (%) | 8 (35) | 32 (26) | 0.57 | ||
BJI mechanisms | |||||
haematogenous, n (%) | 3 (13) | 37 (31) | 0.14 | ||
inoculation, n (%) | 20 (87) | 74 (61) | 0.032 | 0.020 | 3.7 (1.2–11.3) |
Contiguity, n (%) | 0 | 10 (8.3) | 0.36 | ||
Clinical features | |||||
Fever, n (%) | 10 (43) | 48 (40) | 0.66 | ||
Sinus tract, n (%) | 7 (30) | 48 (40) | 1 | ||
Abscess, n (%) | 3 (13) | 12 (9.9) | 0.4 | ||
Biological features | |||||
Maximum CRP value (mg/L) | 163 (±69.1) | 171 (±120) | 0.9 | ||